RADX Radiopharm Theranostics Ltd


$ 4.60 $ -0.15 (-3.09 %)    

Thursday, 20-Nov-2025 15:37:24 EST
QQQ $ 585.63 $ -26.04 (-4.26 %)
DIA $ 458.16 $ -8.52 (-1.83 %)
SPY $ 652.74 $ -20.16 (-3 %)
TLT $ 89.28 $ 0.29 (0.33 %)
GLD $ 374.81 $ -0.37 (-0.1 %)
$ 4.62
$ 4.85
$ 4.39 x 2,600
$ 4.80 x 200
$ 4.65 - $ 5.22
$ 3.50 - $ 50.82
7,134
na
na
$ 0.68
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company fo...

Core News & Articles

Previous comprehensive preclinical proof-of-concept Biodistribution studies of RAD 402 in mouse xenografts showed strong tumour...

Core News & Articles

Early patient data from Phase 2b clinical trial showed significant and selective tumor uptake in brain metastases compared to M...

Core News & Articles

Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceut...

Core News & Articles

Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from s...

Core News & Articles

Financial updateThe following is a summary of the Appendix 4C Cash Flow Report:The year-end closing cash balance was $29.12 mil...

Core News & Articles

- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceu...

Core News & Articles

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, &, ldquo, Radiopharm&, rdquo, or the &, ldquo, Company&, rdquo,...

Core News & Articles

Brookline Capital analyst Kemp Dolliver initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and an...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION